Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2016
At a glance
- Drugs Octocog alfa (Primary) ; Rurioctocog alfa
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Bayer
- 22 Dec 2016 Results published in the Clinical Pharmacokinetics
- 19 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 16 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Oct 2015 as per ClinicalTrials.gov record.